Overview

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. As of December 31, 2011, its product portfolio includes four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). As of December 31, 2011, BioMarin conducted clinical trials on a number of investigational product candidates for the treatment of various diseases, including GALNS; PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU); BMN-701, an enzyme replacement therapy; BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers, and BMN-111, a peptide therapeutic for the treatment of achondroplasia. In January 2013, the Company acquired Zacharon Pharmaceuticals.

Endorsements